Hélène Ste-Croix

Biochemistry, Genetics and Molecular Biology · Life Sciences

6h-index466citations16works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Histone Deacetylase Inhibitors Research(7), Protein Degradation and Inhibitors(7), Cancer, Hypoxia, and Metabolism(5), Liver physiology and pathology(4), Hepatocellular Carcinoma Treatment and Prognosis(2)

Publications16 total

Data from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Table 1 from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Table 1 from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Table 2 from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Table 2 from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Data from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Abstract 1790: The combination of MGCD265, a Met/VEGFR inhibitor in clinical development, and erlotinib potently inhibits tumor growth by altering multiple pathways including glycolysis
Cancer Research·2012· 13 cited
Abstract 3610: Potent preclinical anti-tumor activity of MGCD265, an oral Met/VEGFR multitargeted kinase inhibitor in clinical development, in combination with taxanes
Cancer Research·2011
Potent preclinical antitumor activity of MGCD265, an oral Met/VEGFR kinase inhibitor in phase II clinical development, in combination with taxanes or erlotinib.
Journal of Clinical Oncology·2010· 18 cited
Abstract 3612: Potent preclinical anti-tumor activity of MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor in Phase II clinical development, in combination with an EGFR inhibitor
Cancer Research·2010· 3 cited
Abstract 3609: MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor in Phase II clinical development, potently inhibits clinically relevant Met mutants
Cancer Research·2010
N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: A novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors
Bioorganic & Medicinal Chemistry Letters·2009· 50 citedOpen Access
N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: A novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors
Bioorganic & Medicinal Chemistry Letters·2009· 34 citedOpen Access
81 POSTER Preclinical pharmacodynamic markers of MGCD265, a potent orally active c-Met/VEGFR multitargeted kinase inhibitor in Phase I clinical trials
European Journal of Cancer Supplements·2008· 3 cited
MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
Molecular Cancer Therapeutics·2008· 333 citedOpen Access
T-cell maturation and clonal deletion in cyclosporine-induced autoimmunity
Journal of Autoimmunity·1991· 12 cited

Frequent Co-authors

Jeffrey M. Besterman(15), Claire Bonfils(12), Marielle Fournel(11), Marie‐France Robert(9), Jinru Wang(9), Jubrail Rahil(9), Sylvain Lefèbvre(9), Pu Yan(7), Marie-Claude Trachy-Bourget(7), Ann Kalita(7), Jianhong Liu(7), Aihua Lu(7), Nancy Z. Zhou(7), Jeffrey Gillespie(7), Oscar Moradei(7), Zuomei Li(7), Isabelle Dupont(7), Normand Beaulieu(6), Christiane R. Maroun(6), Hou Yu(6)